A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer-Reference-Cited by-同舟云学术

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

Published:2012-03-18 Issue:4 Volume:18 Page:521-528
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Ng King Pan,Hillmer Axel M,Chuah Charles T H,Juan Wen Chun,Ko Tun Kiat,Teo Audrey S M,Ariyaratne Pramila N,Takahashi Naoto,Sawada Kenichi,Fei Yao,Soh Sheila,Lee Wah Heng,Huang John W J,Allen John C,Woo Xing Yi,Nagarajan Niranjan,Kumar Vikrant,Thalamuthu Anbupalam,Poh Wan Ting,Ang Ai Leen,Mya Hae Tha,How Gee Fung,Yang Li Yi,Koh Liang Piu,Chowbay Balram,Chang Chia-Tien,Nadarajan Veera S,Chng Wee Joo,Than Hein,Lim Lay Cheng,Goh Yeow Tee,Zhang Shenli,Poh Dianne,Tan Patrick,Seet Ju-Ee,Ang Mei-Kim,Chau Noan-Minh,Ng Quan-Sing,Tan Daniel S W,Soda Manabu,Isobe Kazutoshi,Nöthen Markus M,Wong Tien Y,Shahab Atif,Ruan Xiaoan,Cacheux-Rataboul Valère,Sung Wing-Kin,Tan Eng Huat,Yatabe Yasushi,Mano Hiroyuki,Soo Ross A,Chin Tan Min,Lim Wan-Teck,Ruan Yijun,Ong S Tiong

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.2713.pdf

Reference54 articles.

1. Jänne, P.A., Gray, N. & Settleman, J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat. Rev. Drug Discov. 8, 709–723 (2009).

2. Carella, A.M. et al. New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. Haematologica 82, 478–495 (1997).

3. Schiller, J.H. et al. Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer. N. Engl. J. Med. 346, 92–98 (2002).

4. Keedy, V.L. et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non–small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J. Clin. Oncol. 29, 2121–2127 (2011).

5. Baccarani, M. et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J. Clin. Oncol. 27, 6041–6051 (2009).

Cited by 495 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overcoming cancer drug-resistance calls for novel strategies targeting abnormal alternative splicing;Pharmacology & Therapeutics;2024-09

2. Targeting EGFR with molecular degraders as a promising strategy to overcome resistance to EGFR inhibitors;Future Medicinal Chemistry;2024-08-29

3. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

4. Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer;Cancer Letters;2024-08

5. New insights into cancer pathology learned from the dynamics of cancer‐associated fibroblasts;Pathology International;2024-06-25